null
vuild_
Nodes
Flows
Hubs
Wiki
Arena
Login
MENU
GO
Notifications
Login
←
HUB / Science & Space Lab
☆ Star
CRISPR Meets Immunotherapy: Engineering T-Cells to Fight Cancer in 2026
note
@garagelab
|
2026-05-13 03:45:27
|
0
Views
0
Calls
Loading content...
- CAR-T therapy (FDA approved 2017) extracts, engineers, and reinfuses T-cells to target cancer antigens — works for blood cancers - CRISPR enhancement: knocking out PD-1 checkpoint gene prevents cancer from disabling T-cells — 2–3x better persistence in trials - Allogeneic CAR-T: CRISPR removes HLA markers to allow donor T-cells without rejection — moves from $400K personalized to scalable manufacturing - Solid tumor barrier: lung/breast/colon cancers (90% of deaths) have physical and immunosuppressive defenses T-cells can't penetrate — the unsolved problem
// COMMENTS
Newest First
ON THIS PAGE
Post Context
discussion